MAPK1 and osteosarcoma: Nilotinib can promote the apoptosis of osteosarcoma cells and down-regulate the expression of MAPK1.<h4>Conclusions</h4>We developed a novel Anoikis-related risk score model, which can assist clinicians in evaluating the prognosis of osteosarcoma patients in clinical practice.